
SARS-CoV-2 3CLpro-IN-16
CAS No. 352659-40-6
SARS-CoV-2 3CLpro-IN-16( —— )
Catalog No. M37246 CAS No. 352659-40-6
SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 459 | Get Quote |
![]() ![]() |
10MG | 657 | Get Quote |
![]() ![]() |
25MG | 994 | Get Quote |
![]() ![]() |
50MG | 1371 | Get Quote |
![]() ![]() |
100MG | 1773 | Get Quote |
![]() ![]() |
500MG | 3537 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSARS-CoV-2 3CLpro-IN-16
-
NoteResearch use only, not for human use.
-
Brief DescriptionSARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.
-
DescriptionSARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorSARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number352659-40-6
-
Formula Weight294.37
-
Molecular FormulaC17H14N2OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CSCC(=O)N1C=2C=CC=CC2CCC=3C=CC=CC31
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ren P, et al. Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group. J Med Chem. 2023 Aug 18.?
molnova catalog



related products
-
Usenamine A
Usenamine A is a small molecule compound derived from lichen Usnea longissima that has antitumor activity and can be used in the study of tumors.
-
Vatalanib hydrochlor...
Vatalanib hydrochloride (PTK787; ZK-222584; CGP-797870) functions as an inhibitor of VEGFR2/KDR, displaying an IC50 value of 37 nM .
-
Eldacimibe
Eldacimibe (WAY-ACA-147) is an ACAT2 inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, study of atherosclerosis and hypercholesterolemia.